AbbVie AndroGel Jury Verdict Targets 'Low T' Promotion
In first bellwether trial in testosterone replacement therapy litigation, jury issues $150m verdict against AbbVie for fraudulent misrepresentation of AndroGel.
You may also be interested in...
For second time, judge finds problem with jury verdict against AbbVie; Bayer withdraws its appeal of Xarelto pre-trial rulings pending outcome of Supreme Court case.
Even after multiple bellweather wins, Janssen and Bayer still face claims they did not warn doctors about concomitant use with Plavix and aspirin; as case begins in Philadelphia, plaintiff's attorney tells jury the firms were 'silent,' while defense points to doctors' testimony that a different warning would not have changed their prescribing.
Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.